Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence. March IIeX Health, Philadelphia, PA
|
|
- Kelly Chambers
- 5 years ago
- Views:
Transcription
1 Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence March IIeX Health, Philadelphia, PA
2 Overview Current Landscape Data Sources to generate Real World Evidence Rising needs in Oncology Summary 2018 Ipsos 2
3 Current landscape FDA Sentinel Initiative launched in 2008 for safety surveillance post-approval As of September 2017, the Sentinel System has more than 223 million members within a network of 17 data partners and many more collaborating institutions. The data is largely claims and pharmacy data Acceptance of RWE data for drug approvals Particularly in rare diseases and oncology: single arm trials, historic clinical data as control or reference group to provide information that can define the untreated course of disease. Utilize data in drug development programs for more timely access to innovative, safe and effective medicines to the patients FDA has also used RWE to understand treatment patterns, define target populations and monitor post-approval safety Ipsos 3
4 Drug development cycle Discovery / Preclinical Phase I Phase II Phase III Post Launch / Phase IV Product Value Strategy Competitive Analysis Clinical / Safety Benchmarking Cost Effectiveness Benchmarking Patient Groups Analysis Evidence Map: Gap and Opportunity Analysis Payer Input Reimbursement Landscape Global Payer Review Payer Input HTA Assessment Site of Care Analysis Benchmark Reimbursable File Target Product Profile Develop Value Hypotheses Stakeholder Value Analysis Target population selection Active comparator selection Target endpoints and claims Integrated Devt. Plans HEOR / PRO plans Detailed study designs Dissemination planning Pricing Analysis Pricing Value Concept Early pricing research and range assessment Market / sales projections Filing & Launch Final Value Proposition Reimbursement & Policy Strategy Global and Local Value Dossiers Global Price Corridor Launch Sequence Payer Input Evidence Message Development ICER Scenario Planning Dissemination Strategies Value Expansion New indications New target populations Supporting evidence plans Payer engagement External Advisory Promotional Effectiveness Evidence Generation Evidence Needs Assessment Literature Reviews Meta Analysis Burden of Illness Unmet Needs analysis HTA Assessment PRO Evaluation Trial Simulation Modeling Early Economic Models Cost effectiveness Cost of illness Early Evidence Develop Heterogeneity Res. Treatment Patterns Burden and Cost of Illness Subpopulations Prospective Evidence Generation, Strategy, Phase IV Planning Policy Research Updated Economic Models w/ph III data Budget Impact Trial Extrapolation Risk Benefit Real World Studies Prospective and Retrospective Studies Registries Pragmatic Trials Meta Analyses Policy Research 2018 Ipsos 4
5 Drug development cycle Discovery / Preclinical Phase I Phase II Phase III Post Launch / Phase IV Product Value Strategy Competitive Analysis Clinical / Safety Benchmarking Cost Effectiveness Benchmarking Patient Groups Analysis Evidence Map: Gap and Opportunity Analysis Payer Input Evidence Generation Reimbursement Landscape Global Payer Review Payer Input HTA Assessment Site of Care Analysis Benchmark Reimbursable File Target Product Profile Develop Value Hypotheses Stakeholder Value Analysis Target population selection Active comparator selection Target endpoints and claims Integrated Devt. Plans HEOR / PRO plans Detailed study designs Dissemination planning Pricing Analysis Pricing Value Concept Early pricing research and range assessment Market / sales projections Filing & Launch Final Value Proposition Reimbursement & Policy Strategy Global and Local Value Dossiers Global Price Corridor Launch Sequence Payer Input Evidence Message Development ICER Scenario Planning Dissemination Strategies Value Expansion New indications New target populations Supporting evidence plans Payer engagement External Advisory Promotional Effectiveness Evidence Needs Assessment Literature Reviews Meta Analysis Burden of Illness Unmet Needs analysis HTA Assessment PRO Evaluation Trial Simulation Modeling Early Economic Models Cost effectiveness Cost of illness Early Evidence Develop Heterogeneity Res. Treatment Patterns Burden and Cost of Illness Subpopulations Prospective Evidence Generation, Strategy, Phase IV Planning Policy Research Updated Economic Models w/ph III data Budget Impact Trial Extrapolation Risk Benefit Real World Studies Prospective and Retrospective Studies Registries Pragmatic Trials Meta Analyses Policy Research 2018 Ipsos 5
6 Data sources to generate RWE Clinical measures Patient reported outcomes/quality of Life (QoL) Administrative Insurance Claims Chart Reviews Registries Lab measures Biomarkers Electronic Medical Records Hospital Discharge Data Qualitative Research Treatment use current and history including start/stop dates, dose and reasons for discontinuation/switch Existing Surveys Sales Data Primary Data Collection Adverse events Healthcare resource utilization Social Media and Social Listening 2018 Ipsos 6
7 Data sources to generate RWE Need for comprehensive view of patient journey and opportunities to connect with patients to improve access and outcomes Clinical response Economic Value/Cost-benefit Patient reported outcomes and Impact on Quality of Life Response to federal agencies, payers, clinicians and also patient involvement in decision making 2018 Ipsos 7
8 Rising Needs in Oncology Treatment sequencing Biomarker identification Indication expansion Confirmatory benefit Safety/Dose Modification Nature of the disease Fast pace of research under development Accelerated approvals for new and extended label indications 2018 Ipsos 8
9 Rising Needs in Oncology Leveraging available data sources Oncology monitors EMRs Claims Custom build databases Social Media and Social Intelligence 2018 Ipsos 9
10 Rising Needs in Oncology Leveraging available data sources Oncology monitors EMRs Claims Custom build databases Social Media and Social Intelligence 2018 Ipsos 10
11 Rising Needs in Oncology Leveraging available data sources Oncology monitors EMRs Claims Custom build databases Social Media and Social Intelligence ASCO and its affiliate organizations manage social media channels across several platforms, including Twitter, Facebook, YouTube, LinkedIn, Google+, Storify, and Instagram. Opens the lines of communications between doctors and the patient community like never before 2018 Ipsos 11
12 CASE STUDIES 2018 Ipsos. All rights reserved. Contains Ipsos' Confidential and Proprietary information and may not be disclosed or reproduced without the prior written consent of Ipsos Ipsos 12
13 Real-world usage and Clinical Outcomes: Alectinib among NSCLC Patients OBJECTIVE To provide real-world information on the usage and patient outcomes of those treated with alectinib post-crizotinib progression METHOD Participating oncologists (N=95) in the USA were recruited from an online physician panel to participate in a retrospective patient chart review Physicians abstracted data on patient demographics and clinical history from their medical charts (N=207) Physician and patient characteristics were reported descriptively. Differences in response rates across patient characteristic strata were compared using chi-square tests Clinical outcomes of a newly approved product in a real world setting and understanding the differences in patient profiles, who participated in clinical trials previously 2018 Ipsos DiBonaventura M, Wong W, Shah-Manek B, Schulz M. Real-world usage and clinical outcomes of alectinib among post-crizotinib progression 13 anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA. OncoTargets and Therapy. December 2017, 22(11),75-82.
14 Development of communications strategy for new medication launch OBJECTIVE The objective of this study was to provide a basis for developing a communication strategy for the drug, specifically focusing on patient journey. METHOD For patient journey and typology components, researcher based content analyses on patient generated online conversations Key word analysis for search engine optimization phase of the study Qualitative exploration of collected posts to identify overarching issues (including openness to new treatment options, information seeking behavior and disease burden) FIRST SYMPTOMS OPPORTUNITY ZONE Squeeze/ Cut open OPPORTUNITY ZONE REPRESSION DIFFERENT MISDIAGNOSIS & DOCTORS CHANGE PRE-DIAGNOSIS 10+YEARS Shame/ Embarassment CONCERN STRONGER SYMPTOMS Causes/ Therapy Balms/ Creams ADVANCED SYMPTOMS Assumption Confrontation With assumption Shame/ Pain Strong pain DIAGNOSE PHASE 2 OPPORTUNITY ZONE Complete surgery Fear of surgery/ googling images Incurable! ACCEPTANCE Short term freedom of symptoms Emotional Support Social Assistance Depression/ Wound care HELPLESSNESS NEW SYMPTOMS Pain/ Employment/ Self-disgust/ Psyche Numerous surgical Little interventions consulting Further surgery PHASE 3 Clinic Fear of surgeries/ Wound care/ Employment/P ain ADVANCED SYMPTOMS OPTIMISM OPPORTUNITY ZONE DESPAIR Emotional support/ Wound care Social support In addition, quantitative metrics were tabulated Phases: Repression, Acceptance, Optimism, Concern, Helplessness, Despair Deeper insights on patient journey to inform communication strategies of the product 2018 Ipsos Presented at MR conference in 2016, Germany; Study designed and executed by the German Rx and SMX teams 14
15 Summary Growing need to leverage existing data sources, custom built databases and innovative methods like social intelligence to generate RWE solutions in comparatively shorter time span with reasonable cost and resources Comprehensive approach to assess effectiveness, cost and drug access Create value proposition and frameworks in understanding the need, priority and value of the drug to the providers 2018 Ipsos 15
16 Bringing together, in addition to leveraging currently available resources to assess clinical, PROs, cost/benefit; utilizing novel approaches like customized data builds & social intelligence provide a comprehensive story to understand the patient experiences of the product and the value of the drug in a real world setting Customized data builds Comprehensive understanding of Patient Experience Product Impact and Value in the Real World 2018 Ipsos 16
17 Thank you Chris Blanchette, PhD, MBA Senior Vice President, Global Evidence, Value and Access Chitra Karki, MPH Director, Global Evidence, Value and Access 2018 Ipsos 17
Big Data & Predictive Analytics Case Studies: Applying data science to human data Big-Data.AI Summit
Big Data & Predictive Analytics Case Studies: Applying data science to human data 1.03.2018 Big-Data.AI Summit Dr. Arnim Jost, Commercial Director Technology Copyright 2017 IQVIA. All rights reserved.
More informationIs Social Intelligence Creating a Paradigm Shift?
Is Social Intelligence Creating a Paradigm Shift? Ipsos Stefan Maas highlights why using online patient generated conversations can help develop your communication strategy CASE STUDY Is Social Intelligence
More informationSanofi Press Breakfast on Behavioral Science. Friday 22 September 2017
Sanofi Press Breakfast on Behavioral Science Friday 22 September 2017 Agenda WHY UNDERSTANDING BEHAVIORS CAN UNLOCK CARE SUCCESS 8.45-9.00 Welcome coffee 9.00 Kick-off 9.00-9.10 Introduction by Alexandra
More informationWhat do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden
What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden Sunil Ramkali Account Director, W Communication Agency 11 th November 2014
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationREAL WORLD DATA GENERATION FOR MARKET ACCESS PURPOSES. Marcin Balcerzak Research Team Lead Farenta Oy
REAL WORLD DATA GENERATION FOR MARKET ACCESS PURPOSES Marcin Balcerzak Research Team Lead Farenta Oy AGENDA Real world evidence in market access landscape: demands & requirements Case studies: Product
More informationDelivering Value Through Personalized Medicine: An Industry Perspective
Delivering Value Through Personalized Medicine: An Industry Perspective Josephine A. Sollano, Dr.PH Head, Global HEOR and Medical Communications Pfizer Oncology, NY, USA josephine.sollano@pfizer.com What
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationSound Off DR. GOOGLE S ROLE IN PRE-DIAGNOSIS THROUGH TREATMENT. Ipsos SMX. June 2014
Sound Off DR. GOOGLE S ROLE IN PRE-DIAGNOSIS THROUGH TREATMENT June 2014 Ipsos SMX : Sound bits (of advice) and bites (of research) from Ipsos SMX Ipsos social media research division, dedicated to providing
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationWe see health care. differently. Comprehensive data Novel insights Transformative actions Lasting value
We see health care differently Comprehensive data Novel insights Transformative actions Lasting value 24 Hours of Optum data: Creating a more complete health picture We capture: Largest EHR dataset 90
More informationPatients Driving Progress
Patients Driving Progress Ellen V Sigal, PhD WIN Symposium 2018 June 25, 2018 Paris, France Nothing to disclose The Evolution of Patient Advocacy The Agnew Clinic, Thomas Eakins (1899) Partial mastectomy
More informationImmunotherapy in Oncology
Emerging Markets Market Access & Health Outcomes Immunotherapy in Oncology Comparing and contrasting payer and oncologist perspectives on the impact of a wave of immunotherapies (especially PD-1/PD-L1)
More informationEvolution of the Oncology Landscape. Emerging Trends and Focus on Value
Emerging Trends and Focus on Value 2 Introduction Owing to advances in early detection and treatment of cancer, people are living longer after a cancer diagnosis. Consequently, this has led to a growing
More informationINSIGHTS INTO ADHD CARE IN GERMANY BASED ON SHI CLAIMS DATA 03. March Results of the CoCA Study (Horizon 2020)
03. March 2017 INSIGHTS INTO ADHD CARE IN GERMANY BASED ON SHI CLAIMS DATA Results of the CoCA Study (Horizon 2020) Who are we? HGC looks back on close to 30 years of experience in the health care sector
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationLeveraging Electronic Health Data in a Multinational Clinical Trial: Early Learnings from the HARMONY- OUTCOMES EHR Ancillary Study
Leveraging Electronic Health Data in a Multinational Clinical Trial: Early Learnings from the HARMONY- OUTCOMES EHR Ancillary Study Emily O Brien, PhD Assistant Professor Lesley Curtis, PhD Professor Department
More informationAdvancing Molecular Diagnostics for Oncology: Partnerships to Accelerate Evidence Development
Advancing Molecular Diagnostics for Oncology: Partnerships to Accelerate Evidence Development Assessing Clinical Utility with Real-World Evidence IOM/CMTP Workshop May 2012 G. Rossi Ph.D. V.P. Payer and
More informationInnovative Risk and Quality Solutions for Value-Based Care. Company Overview
Innovative Risk and Quality Solutions for Value-Based Care Company Overview Meet Talix Talix provides risk and quality solutions to help providers, payers and accountable care organizations address the
More informationIntroducing NCCN Academy for Excellence & Leadership in Oncology April Program Overview
Introducing NCCN Academy for Excellence & Leadership in Oncology April 2009 Program Overview In 2009, NCCN will launch the NCCN Academy for Excellence & Leadership in Oncology, a series of oncology certificate
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More informationWelcome and Texas DSHS Overview
Welcome and Texas DSHS Overview July 24, 2015 Heart Attack and Stroke Systems of Care Summit: A Focus on Quality Improvement through the Texas Heart Attack and Stroke Data Collection Initiative Disclosure
More informationIntegrating the Patient Perspective Into Value Frameworks
Integrating the Patient Perspective Into Value Frameworks Avalere Health An Inovalon Company August, 2017 Speakers and Agenda Josh Seidman, PhD Senior Vice President jjseidman@avalere.com @jjseidman 1.
More informationArthritis Foundation Patient Insights. Understanding, Serving and Helping Millions of People With Arthritis
Arthritis Foundation Patient Insights Understanding, Serving and Helping Millions of People With Arthritis In the United States, 54 ADULTS 1IN 4 have doctor-diagnosed arthritis. 2/3 are under the age of
More informationOctober 4 6, 2017 The W Hotel, Chicago, IL
October 4 6, 2017 The W Hotel, Chicago, IL Register for this and future events at https://drgconferences.com WELCOME Cancer affects us all. Some reading this have survived it. Many have watched loved ones
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationREFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m
More informationREFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India
More informationAre Payers Getting Tougher? Essential Insights on How to Smooth Acceptance of New Genetic Tests
Are Payers Getting Tougher? Essential Insights on How to Smooth Acceptance of New Genetic Tests Jacqueline Huang Senior Associate Reimbursement Policy and Government Affairs Objectives Learn how payers
More informationREFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif
More informationREFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India
More informationMember-centered cancer care In Georgia
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Member-centered cancer care In Georgia Ira Klein, MD, MBA, FACP GASCO Annual Meeting September 5, 2015 > One
More informationBuilding a Digital Home to Provide Patient Support, Education and Clinical Trial Awareness
Building a Digital Home to Provide Patient Support, Education and Clinical Trial Awareness unlocking the potential of multi-stakeholder communities and the families it serves Rare Drug Development and
More informationREFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012
More informationLiver Forum Cirrhosis Working Group Arun J. Sanyal
Liver Forum Cirrhosis Working Group Arun J. Sanyal Z Reno Vlahcevic Professor of Medicine VCU School of Medicine Richmond, VA 2 Liver Forum 8 DRUG DEVELOPMENT PATHWAYS Regular approval pathway: based on
More informationChronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA
Chronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA US Chronic Care has outperformed the market by a factor 2-3x and continues
More informationIntroduction. Rare Disease Research, Health Technology Assessment and Evidence for Reimbursement FORUM
Rare Disease Research, Health Technology Assessment and Evidence for Reimbursement FORUM ISPOR 20 th Annual European Congress, Glasgow 6 th November, 2017 Introduction Sandra Nestler-Parr Rare Access,
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationVALUE FRAMEWORKS IN HTA Are Value Frameworks Useful in Helping Canadian Cancer Systems Determine Funding for New Therapies?
VALUE FRAMEWORKS IN HTA Are Value Frameworks Useful in Helping Canadian Cancer Systems Determine Funding for New Therapies? April 24, 2017 Background Therapeutic innovation continues to grow as new therapies
More informationWatson Summit Prague 2017
Watson for Oncology Matěj Adam Watson Health Executive May 2017 Watson Summit Prague 2017 an IBM Company Leadership & 23 Years Patent Leadership Research Spend Global Presence Technology 7300+ 2015 $6B
More informationOverview from the Division of Cancer Prevention and Control
Overview from the Division of Cancer Prevention and Control Lisa C. Richardson, MD, MPH Director, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC) Advisory Committee
More informationOAMT ONCOLOGY ACCOUNT MANAGEMENT TRAINING. September 20 22, 2016 ARIA Resort & Casino, Las Vegas, NV. For the Life Sciences Industry
OAMT ONCOLOGY ACCOUNT MANAGEMENT TRAINING For the Life Sciences Industry September 20 22, 2016 ARIA Resort & Casino, Las Vegas, NV Register at DecisionResourcesGroup.com/Events DEAR COLLEAGUE, Cancer affects
More informationCommunity Benefit Strategic Implementation Plan. Better together.
Community Benefit Strategic Implementation Plan 2016 2019 Better together. Table of Contents Introduction... 4 Priority 1: Community Health Infrastructure... 5 Objective 1.1: Focus resources strategically
More informationThe MetroHealth System. Creating the HIT Organizational Culture at MetroHealth. Creating the HIT Organizational Culture
CASE STUDY CASE STUDY The MetroHealth System Optimizing Health Information Technology to Increase Vaccination Rates The MetroHealth System in Cleveland, Ohio, was the first safety-net health care system
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationCADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs
Cancer Drug Funding Sustainability: From Recommendations to Action CADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs Contributing authors Provincial Drug Reimbursement
More informationWednesday, July 13, 2016 National Press Club Washington, DC
Wednesday, July 13, 2016 National Press Club Washington, DC National Vision & Eye Health Surveillance System Jinan Saaddine MD, MPH, CDC Vision Health Initiative David Rein PhD, NORC at the University
More informationResponding to the Spirit of 21 st Century Cures Legislation
Responding to the Spirit of 21 st Century Cures Legislation Clinical Research Forum Industry Forum September 25, 2017 Joe Selby, MD MPH Executive Director, PCORI For Today Doing Research Differently: Patient-Centered
More informationData Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis
February, 13th 2018 Data Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies:
More informationIn all of these roles, I've used healthcare data to drive strategy for the life sciences industry.
Intro: When you take a magnifying glass and look at a picture, you see that it's made up of thousands of dots and when you pull back, those dots become the details that create the picture. There's real
More informationThe pcodr review also provided contextual information on ALK mutation testing.
only approximately 4% of NSCLC patients are expected to have the ALK mutation. perc further discussed these estimates in the context of the feasibility of implementing a funding recommendation for crizotinib.
More informationACO Congress Conference Pre Session Clinical Performance Measurement
ACO Congress Conference Pre Session Clinical Performance Measurement Lynne Rothney-Kozlak, MPH Interim VP, ACO Collaborative (Independent Consultant) October 25, 2010 Agenda for Presentation 1. The Framework
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More information2018 Edition The Current Landscape of Genetic Testing
2018 Edition The Current Landscape of Genetic Testing Market growth, reimbursement trends, challenges and opportunities November April 20182017 EXECUTIVE SUMMARY Concert Genetics is a software and managed
More informationHOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK
HOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of
More informationBusiness Contributions to Setting New Research Agendas: Business Platform for Nutrition Research (BPNR)
Business Contributions to Setting New Research Agendas: Business Platform for Nutrition Research (BPNR) Purpose How can we promote more investment into public research? How can we promote improved uptake
More informationTargeted Agent and Profiling Utilization Registry
Targeted Agent and Profiling Utilization Registry Richard L. Schilsky, MD, FACP, FASCO Senior Vice President and Chief Medical Officer American Society of Clinical Oncology Disclosure Information Richard
More informationAdvaMed Medtech Value Assessment Framework in Practice
AdvaMed Medtech Value Assessment Framework in Practice Application of the Medtech Value Assessment Framework to Cymedica s e-vive System Value Framework Overview In response to the growing need to demonstrate
More informationPatrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference
Patrick J. Sullivan, President & CEO March 7, 2016 Raymond James 37 th Annual Institutional Conference Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's
More informationAdvaMed Medtech Value Assessment Framework in Practice
AdvaMed Medtech Value Assessment Framework in Practice Application of the Medtech Value Assessment Framework to Rotation Medical s Bioinductive Implant Value Framework Overview In response to the growing
More informationCurrent Landscape: Value Assessment Frameworks. Kimberly Westrich, MA Vice President, Health Services Research
Current Landscape: Value Assessment Frameworks Kimberly Westrich, MA Vice President, Health Services Research Updated June 2016 Background There are many aspects to the U.S. health care system, as well
More informationlimitations of the indirect evidence submitted to pcodr, perc concluded that there is considerable uncertainty on how alectinib compares with ceritinib with regard to outcomes important to decision making
More informationA healthy dose. of social media 2015 checkup. How Ohio hospitals use social channels to build relationships. Exclusive research by
A healthy dose of social media 2015 checkup How Ohio hospitals use social channels to build relationships Exclusive research by A healthy dose of social media Executive summary When hospitals need to communicate,
More informationPaying for Genomic Testing and Associated Care. Scott Ramsey, MD, PhD FRED HUTCHINSON CANCER RESEARCH CENTER
Paying for Genomic Testing and Associated Care Scott Ramsey, MD, PhD FRED HUTCHINSON CANCER RESEARCH CENTER Cost of Cancer Genome Sequencing Will vary with: Approach Whole genome, exome, transcriptome
More informationOncology Special Interest Group
Oncology Special Interest Group Open Meeting Tuesday, 10 November 2015 ISPOR 18 th Annual European Congress MiCo Milano Congressi, Milan, Italy Compounds in Development for Top 10 Therapeutic Areas a Number
More informationRD-ACTION DISSEMINATION PLAN TABLE I - STAKEHOLDER ANALYSIS
RD-ACTION DISSEMINATION PLAN TABLE I - STAKEHOLDER ANALYSIS Stakeholder Group Interest in RD-Action Dissemination purpose Channels of Dissemination (WHO) (WHY) (WHY) (HOW) Partners of RD-Action & members
More informationThe New Medtech Economic Reality MassMEDIC Annual Meeting
The New Medtech Economic Reality MassMEDIC Annual Meeting Susan Posner Vice President sposner@healthadvances.com May 1, 2012 The New Medtech Reality The economic downturn coupled with the focus on health
More informationReal world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform
Real world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform Catherine Reed, Lilly on behalf of ROADMAP consortium 3 rd Nordic conference on Real World Data, 28-29 November
More informationPopulation Health 2.0 through Personalized Medicine
DISCOVERING WHAT WORKS. AND FOR WHOM. Population Health 2.0 through Personalized Medicine Colin Hill CEO and Co-Founder "Fifty-five percent of drugs used in America don't work for the patients they are
More informationNational Survivorship and QoL Research:
National Survivorship and QoL Research: Impact on Interventions, Guidelines, and Resources Kevin D. Stein, PhD, Vice President, Behavioral Research, Director, Behavioral Research Center, American Cancer
More informationStrategic Plan
Strategic Plan 2013-2015 The key to a strong, responsive organization is a clearly defined mission, complete with specific goals and intended outcomes. Our strategic goals are essential to the association
More informationPatient Group Pathway Model to Accessing Cancer Clinical Trials in Canada
Patient Group Pathway Model to Accessing Cancer Clinical Trials in Canada Barry D. Stein President CCC What problems are we trying to solve? 1. Too few cancer patients are enrolled in clinical trials.
More informationLife Sciences Consortium Task Force Report to The National Cancer Policy Forum Workshop
Life Sciences Consortium Task Force Report to The National Cancer Policy Forum Workshop Gregory A. Curt, MD, Chair U.S. Medical Science Lead, Emerging Products AstraZeneca -Oncology CEO Roundtable-I May
More informationCOVERAGE WITH EVIDENCE DEVELOPMENT
COVERAGE WITH EVIDENCE DEVELOPMENT OVERVIEW AND USE TO PROMOTE BIOMARKER DEVELOPMENT IOM National Cancer Policy Forum Sean Tunis, MD, MSc November 10, 2014 CED DEFINITION AND PURPOSE Reimbursement that
More informationAchieving Operational Excellence in Prospective Observational Research
Achieving Operational Excellence in Prospective Observational Research Louise Parmenter PhD, MSc VP, Global Head of Operations, Epidemiology & Outcomes Research Ombretta Palucci Senior Director, EMEA RWLP
More informationUnleashing Big Data in Oncology: Making Real World Cancer Data Useful
June 18, 2015 Unleashing Big Data in Oncology: Making Real World Cancer Data Useful Bobby Green, MD MSCE Vice President, Clinical Strategy Senior Medical Director bobby@flatiron.com www.flatiron.com Funding
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationTactics to Make Telehealth Pay Off
Tactics to Make Telehealth Pay Off Lin Li, Ph.D. Philips Research North America Kathleen Sullivan, RN, MSN Dignity Health 2013 NAHC Annual Meeting Oct, 2013 Today s discussion Insights gained from market
More informationOpportunity and Challenge
Opportunity and Challenge Implementation of Comparative Effectiveness Research: The Patient Protection and Affordable Care Act Dr. Ellen V. Sigal, Chair & Founder, Friends of Cancer Research Comparative
More informationAcurian on. Patient Centricity and Enrollment Certainty
Acurian on Patient Centricity and Enrollment Certainty With the site-first approach to enrollment feasibility and completion continuing to struggle, sponsors are recognizing the need to embrace a patient-first
More informationAddressing Gaps in MS Care. November 6, :00 AM - Noon
Addressing Gaps in MS Care November 6, 2015 11:00 AM - Noon Learning Objectives Understand and confidently communicate the barriers to MS care caused by the shortage of healthcare providers with MS experience,
More informationUsing Real-World Data/Evidence in Regulatory Decision Making
Using Real-World Data/Evidence in Regulatory Decision Making Chi-Hsun Chen, M.D. Senior Team Leader/Medical Reviewer Center for Drug Evaluation, Taiwan 1 Outlines 0 8 1 What are RWD & RWE? From RWD to
More informationBending the Cost Curve Through Comparative Effectiveness Research. ASCO 2012 Sean Tunis MD, MSc June 2, 2012
Bending the Cost Curve Through Comparative Effectiveness Research ASCO 2012 Sean Tunis MD, MSc June 2, 2012 Evidence Summary: Radiation Therapy for Comparisons Clinically Localized Prostate Cancer Disease
More informationImproving Type 2 Diabetes Therapy Compliance and Persistence in the Kingdom of Saudi Arabia
July 2016 Improving Type 2 Diabetes Therapy Compliance and Persistence in the Kingdom of Saudi Arabia Appendix PATIENT ACTIVATION Introduction This Appendix document provides supporting material for the
More informationInnovator Case Studies: Oncology Networks
Innovator Case Studies: Oncology Networks J. Ike Nicoll Chief Executive Officer Cancer Clinics of Excellence Alan Armer, Ph.D. Vice President, Research & Development Catholic Health Initiatives Cancer
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationValue-based frameworks in oncology
28 November 2017 Value-based frameworks in oncology Clarity or confusion? Prepared for: European Statistical Meeting on Latest Trends in HTA Prepared by: Jan McKendrick, Senior Director PRMA Consulting
More informationCSQI BACKGROUNDER What is The Cancer Quality Council of Ontario (CQCO)? What does CQCO do? What is the Cancer System Quality Index?
CSQI BACKGROUNDER What is The Cancer Quality Council of Ontario (CQCO)? Established in 2002 by the Ministry of Health and Long-Term Care (MOHLTC), the Cancer Quality Council of Ontario (CQCO) is an arm
More informationThe Academy Capitol Forum: Meet the Experts. Diagnosing Which Health Treatments Improve Outcomes: A PCORI Overview and How to Get Involved
The Academy Capitol Forum: Meet the Experts Diagnosing Which Health Treatments Improve Outcomes: A PCORI Overview and How to Get Involved Presenter: Gregory Martin, Deputy Directory of Stakeholder Engagement
More informationREFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - Executive Summary Below table provides a summary of Belviq for obesity in the nine major pharmaceutical markets during the forecast
More informationTrends in Oncology: Preparing for Seismic Change. ASCO s Clinical Affairs Department
Trends in Oncology: Preparing for Seismic Change Association of Northern California Oncologists May 20, 2015 Thomas R. Barr, MBA Director, Business Metrics and Analysis Clinical Affairs Department ASCO
More informationIrish Experts Launch Global Report and Call for Increased Focus on Metastatic Breast Cancer
Irish Experts Launch Global Report and Call for Increased Focus on Metastatic Breast Cancer Early detection does not help survival for metastatic breast cancer patients - average survival for women with
More informationCost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma
Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following
More informationThe National Vaccine Advisory Committee: Reducing Patient and Provider Barriers to Maternal Immunizations
The National Vaccine Advisory Committee: Reducing Patient and Provider Barriers to Maternal Immunizations Executive Summary Maternal immunization provides important health benefits for pregnant women and
More informationChronic Diseases/Maternal & Child Health Michigan Department of Community Health, Lifecourse Epidemiology and Genomics Division
Chronic Diseases/Maternal & Child Health Michigan Department of Community Health, Lifecourse Epidemiology and Genomics Division Lansing, MI Assignment Description The Fellow will be working with mentors
More informationASCO s CLINICAL AFFAIRS DEPARTMENT
ASCO s CLINICAL AFFAIRS DEPARTMENT Walter Birch, Division Director Walter.Birch@asco.org New Clinical Affairs Department Helping practices survive and thrive today AND in the future Approved by the Board
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationOUR GOALS. For the detailed plan visit
STRATEGIC PRIORITIES When organizations reach milestones such as a golden anniversary, leadership should not only seize the opportunity to revel in past successes, but also proceed with a renewed focus
More information